Skip to main content

Table 2 Summary of therapeutic and survival data in patients who received curative resection.

From: Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study

  Mucosal melanoma (n = 87), N (%) Ocular melanoma
N (%)
  Total Anorectum Genitourinary Gastrointestinal Nasal Oral Maxillary sinus  
No. 87 31 17 1 23 11 4 13
   R1 resection 25 2(6.5) 5(29.4) 0 12(52.2) 5(45.5) 1(25.0) 5(38.5)
   R0 resection 62 29(93.5) 12(70.6) 1(100) 11(47.8) 6(54.5) 3(75.0) 8(61.5)
Adjuvant treatment         
   No 53 20(64.5) 8(47.1) 1(100) 18(78.3) 4(36.4) 2(50.0) 7(53.8)
   Chemotherapy 22 10(32.3) 6(35.3) 0 0(0.0) 4(36.4) 0 2(15.4)
IFN 14 5 4 0 0(0.0) 3 0 2
Cytotoxic 8 5 2 0 0(0.0) 1 0 0
   Radiotherapy only 14 1(3.2) 3(17.6) 0 5(21.7) 3(27.2) 2(50.0) 4(30.8)
Relapse after resection         
   None 36 11(35.5) 7(41.2) 0 12(52.2) 5(45.4) 1(25.0) 6(46.2)
   Local relapse 21 7(22.6) 1(5.9) 0 8(34.8) 4(36.4) 1(25.0) 4(30.8)
   Systemic 30 13(41.9) 9(52.9) 1(100) 3(13.0) 2(18.2) 2(50.0) 3(23.0)
Palliative treatment after recurrence (total n = 51)         
   Chemotherapy only 9 (17.6) 3 2 0 3 1 0 3(42.9)
   Radiotherapy only 10 (19.6) 3 2 0 2 3 0 1(14.3)
   Resection 6 (11.7) 2 1 1 0 1 1 0
Current status         
   No evidence of disease 31 (35.6) 12(38.7) 7(41.2) 0 7(30.4) 5(45.5) 0(0.0) 5(38.5)
   Alive with disease 6 (6.9) 1(3.2) 1(5.9) 0 2(8.7) 1(9.0) 1(25.0) 2(15.3)
   Dead of disease 50 (57.5) 18(58.1) 9(52.9) 1(100) 14(60.9) 5(45.5) 3(75.0) 6(46.2)
Overall Survival (%)         
   2 years 59.7 61.3 68.4 - 46.9 53.0 75.0 73.3
   5 years 31.9 30.6 39.1 - 25.1 39.8 - -
Median survival months (95% CI) 34.6
(24.5-44.7)
28.6
(18.2-38.9)
43.9
(29.6-58.2)
7.5
(NA)
23.4
(7.4-8.9)
38.9
(13.4-64.4)
24.4
(0-49.3)
51.2
(NA)
\